Navigation Links
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its,Ghrelin Antagonist Program at the American Diabetes Association's,Annual Meeting

nd debilitating metabolic disorders such as Type 2 diabetes and obesity," stated Peter DiStefano, Ph.D., Chief Scientific Officer. "We are rapidly advancing our EX-1350 ghrelin antagonist and plan to initiate Phase I testing early next year."

According to the International Diabetes Federation, Type 2 diabetes affects 195 million people worldwide, and the number of sufferers could top 330 million by 2025.

Elixir has filed broad intellectual property protection on all aspects of the ghrelin antagonist program including composition of matter protection covering five novel compound classes and their therapeutic uses.

About Elixir Pharmaceuticals

Elixir is a Cambridge, MA-based biopharmaceutical company focused on developing and commercializing drugs to treat and prevent metabolic disease, prevent age-related diseases, ultimately extending the quality and length of human life.

In addition to its ghrelin antagonist program, the Company has leveraged its knowledge of ghrelin biology and pharmacology by licensing a small molecule ghrelin agonist (designated EX-1314) from Bristol-Myers Squibb Company in April 2005. EX-1314 binds selectively to the ghrelin receptor and mimics the body's naturally occurring ghrelin. In doing so this novel, orally available agent is capable of stimulating appetite, gastric motility and the release of growth hormone. Elixir is currently in IND-enabling studies with EX-1314 targeting a variety of therapeutic indications.

Further, in March 2006, Elixir in-licensed North and South American rights to Glufast(R) (mitiglinide calcium hydrate), an insulin secretagogue, which lowers post-meal glucose levels by improving the body's own ability to produce insulin. Already marketed in Japan, Glufast has undergone extensive clinical development demonstrating the product's ability to safely and effectively treat Type 2 diabetes.

Elixir has also developed expertise and a broad IP portfolio of more than twenty p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
(Date:11/9/2009)..., MIAMI, Nov. 9 ISTA P...nced additional results from the Company,s Bepreve...5% Phase 3 clinical studies. These results were p...ting of the American College of Allergy, Asthma &a...In a poster presentation titled, "Treatment of Ocu...
(Date:11/9/2009)..., SUNNYVALE, Calif., Nov. 9 /PRNewswire-FirstCal...harmaceutical company focused on developing and co...the treatment of immune mediated diseases and canc...sident, Preclinical Development will provide an ov... Merriman Curhan Ford,s 6th Annual Investor Summit...
(Date:11/9/2009)..., SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswir...ay announced that on November 5, 2009, it received...q") stating that the Nasdaq Hearing Panel has gran... NASDAQ Global Market subject to the condition tha...er 31, 2009, the proposed merger (the "Merger") co...
Breaking Medicine Technology:ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3David Yap receives Amethyst Award 51065 1LocumTenens com Expands Service Lines to Include Primary Care 51062 1LocumTenens com Expands Service Lines to Include Primary Care 51062 2LocumTenens com Expands Service Lines to Include Primary Care 51062 3Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 1Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 2Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 3Insite Security Partners With WorldClinic to Offer Global Medical Support to Clients 51057 4
...3 Telik, Inc.,(Nasdaq: TELK ) announced it will ... of TELINTRA(R) (ezatiostat HCl) Tablets at the 49...ology. The presentation is,scheduled for Saturday,...,and B4 at the Georgia World Congress Center in At...608) is titled: "Phase 1 Dose Escalation Study of,...
...ance to Phase III Clinical Trial, PALO ALTO, Cali...d: AVGO), a late-stage biotechnology company that,...eurodegenerative,diseases, today announced positiv...AL-08, the Company,s second generation proprietary...ose of the trial was to determine which,of two com...
Other Medicine Technology:Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) 2Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) 3Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) 4
(Date:11/9/2009)...9 New Mayo Clinic resea...rolapse dramatically reduces patient hospital st...sented this week at the North Central Section of t...Ariz. ,, (Logo: http://www.newscom.com/cgi-b... Additional audio and video resources, including e...
(Date:11/9/2009)...erimental Procedure for Preteen Son - ,, PHIL...rents of children with cancer, the hopeful news is...ved for decades. Among the bad news -- treatments ..., Boys diagnosed with cancer who have reached pu...eir fertility: before undergoing cancer treatment,...
(Date:11/9/2009)...wswire/ -- , , WHAT: All PETCO stores natio... workshop facilitated by specially trained in-stor...ember 14 at 2 p.m. During the 30-minute, ...tritional needs of, their dogs and ca... good pet nutrition, receive an assessment...
(Date:11/9/2009)...in French . , , Montreal, November 9, 2009 ...e. In human bodies trillions of cells are coupled,... composed. Yet these don,t come in twos, they are...e these complex cell networks are the backbone of ...or ways to splice cell clusters down to their orig...
(Date:11/9/2009)...onstruction industry, respiratory disease, often l...r, is a major public health concern. Studies led ...inia Tech,s School of Construction, have shown tha...tive in reducing the dust that causes these health...e technology remains very low. , To find out why...
Breaking Medicine News(10 mins):Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 2Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 4Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3
...risis, YONKERS, N.Y., June 9 Some of the biggest...GE Money, Citigroup, and,Chase, are pushing risky ...,to the latest issue of Consumer Reports, which de... today, it could more,than triple to $150 billion ...
...f retina damage , , MONDAY, June 9 (Health... the progression of eye disease in diabetes patien... Eye Institute at the University of California, Lo...erience reductions in visual acuity (sharpness). B...
...kely Demand Similar,Treatment Next Year, WASHINGT...ociation (PCMA) released a new ad today warning po...ing doctors and hospitals -- would,likely demand t...ers twice as fast as all the others,will create a ...
...% reporting accidents as result , , MONDAY...ng from a lack of sleep may be a real problem for ..., Interviews with 263 students at the University o...ess. A majority in both groups reported greater da...
...tics can significantly aid healing of the severe t...births, according to researchers at Lucile Packard...versity School of Medicine and Santa Clara Valley ... common complication of childbirth. , As many as ...
...eflon chemicals likely,contaminate area residentia...eeded New Jersey,s ,alert level., - Private resid...DEP., - Testing demanded of all private drinking ...ironmental and labor groups are calling for the te...
Other Medicine News:Health News:Consumer Reports: Patients 'Overdose' on Debt As Lenders, Doctors, and Hospitals Push Risky Credit to Pay for Medical Care 2Health News:Consumer Reports: Patients 'Overdose' on Debt As Lenders, Doctors, and Hospitals Push Risky Credit to Pay for Medical Care 3Health News:Consumer Reports: Patients 'Overdose' on Debt As Lenders, Doctors, and Hospitals Push Risky Credit to Pay for Medical Care 4Health News:Diabetes Drug May Slow Eye Disease 2Health News:New PCMA Ad: Pharmacist 'Prompt Pay' Will Trigger 'Domino Effect' Among Other Medicare Providers 2Health News:Sleepy Driving Prevalent Among Collegians 2Health News:Antibiotics can prevent wound complications of childbirth, Stanford/Packard study finds 2Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 2Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 3
Steroid 21-Hydroxylase (21-OH) Autoantibody RIA
...ELISA test kit is intended for the quantitative de...This exceptionally sensitive ELISA procedure offer...y), providing for accurate establishment of post-a...ventional methods. Furthermore, with the ability t...
...r use with 4, 8, or 12 channel pipettors. Angled s...rly all of the solution. Corners have pouring lips...rgin polystyrene containing no regrinds. Sterile 5...y irradiation. Dimensions: 78 mm W x 152 mm L x 35...
Sterile Individually Packed 100 mL Solution Basins
Medicine Products: